FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company), a licensed producer under the Cannabis Act, announced today that it has completed a strategic investment of $1.5 million in Pharmastrip Corp. and signed a definitive collaboration and profit sharing agreement with the company, effective January 23, 2019. Under the terms of the agreement, FSD will install Pharmastrip proprietary equipment at its facility in Cobourg, Ontario. FSD will use the equipment to manufacture organic medical cannabis infused in oral thin film strips. Pharmastrip will grant FSD an exclusive, perpetual license to manufacture and sell the oral thin film strips in Canada.
- Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications.
- The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets.
- The study aims to show the potential for reduction or elimination of the use of opiates in patients, a major epidemic throughout North America.
- The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.
Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”), today announces the launch of a research partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, M.D. (Head of the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at the University of British Columbia), subject to approval of the University of British Columbia where the proposed clinical trial will take place. The aim of the study is to examine and quantify the efficacy of Canntab products in decreasing the duration and quantity of postoperative use of opioid medications and in the management of preoperative pain. Dr. Garbuz shall be the Lead Investigator for the research study.
FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the Company’s facility and land located at 520 William Street in Cobourg, Ontario has a Fair Market Value of $105,000,000 according to a recent Comprehensive Property Value Assessment by a commercial real estate assessment specialist issued on November 20, 2018.
FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that its Head of Scientific Advisory Board, Dr. Zohar Koren, will attend the 3rd International Medical Cannabis Conference, (“CannX”) in Tel Aviv, Israel from October 14 to 16, 2018.
FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the “Agreement“) with Canntab Therapeutics Limited (CSE:PILL) (“Canntab“), a leader in the rapidly growing cannabis pill market, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License“), and will provide Canntab with space at its facility (the “FSD Facility“), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction“).
FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that it intends to launch a strategic partnership into the Jamaican cannabis market as part of its plan to expand internationally. FSD has signed a Letter of Intent (“LOI”) effective September 10, 2018 with JJAMACANN Inc. (“JJAMACANN”) to form a joint venture operating as FSD Jamaica (“FSD Jamaica”). FSD Jamaica expects to partner locally with Nature’s Purest Limited (“NPL”), a Jamaican corporation with a cultivation license and existing operations in Jamaica.
FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), completed the harvest of its first lot of cannabis and successfully passed microbial testing required by Health Canada under the ACMPR and will be harvesting its second lot this week so as to conduct full analytical testing, thereby positioning FV Pharma to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR.
FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) announced today that its subordinate voting shares are now listed on the Frankfurt Stock Exchange (“FRA”) and are trading under the “WKN: A2JM6M” and the ticker symbol “0K9.” The Company’s subordinate voting shares continue to be listed on the Canadian Stock Exchange (“CSE”) under the ticker symbol “HUGE” and on the OTC in the US under the ticker symbol “FSDDF.”